Tislelizumab and Radiotherapy for Recurrent Cervical Cancer

Inclusion Criteria: 1. The patient voluntarily participates and signs informed consent 2. Aged 18 years of age or older 3. Has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 within 7 days prior to the first dose of study treatment 4. Has recurrent cervical cancer and controllable local treatment, indicating an indication for radiation therapy 5. Willing to accept concurrent radiotherapy combined with Tislelizumab 6. Has measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by the local investigator 7. Has adequate organ function 8. Has expected survival time ≥3 months Exclusion Criteria: 1. Has received prior therapy with an anti-programmed cell death receptor 1 (PD-1), or with an agent directed to another stimulatory or co-inhibitory T-cell receptor 2. Has a known history of Human Immunodeficiency Virus (HIV) infection，active Hepatitis virus infection and active tuberculosis (TB; Bacillus tuberculosis) 3. Has known active central nervous system (CNS) metastases and/or uncontrolled, untreated carcinomatous meningitis with elevated intracranial pressure 4. Has received a major surgery within 4 weeks prior to signing informed consent 5. Not suitable for radiotherapy 6. Reassessment of liver and kidney function and blood routine indexes after radiotherapy did not meet the above criteria 7. Did not meet the other requirements for inclusion by the investigator 8. Judged unqualified of the enrollment requirements by the researcher according to other conditions